Synonyms: WX614 [2] | WXFL-10203614
Compound class:
Synthetic organic
Comment: WXFL10203614 (WX614) is a Janus kinase inhibitor. Its chemical structure was revealed in patent CN111039963A. It is a water-soluble analogue, that was proposed as an oral drug to treat rheumatoid arthritis.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J et al.. (2017)
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Sci Rep, 7 (1): 466. [PMID:28352114] |
2. Wu H, Mao W, Huang Y, Fan L, Chen S. (2018)
Janus kinase inhibitor. Patent number: US20180162879A1. Assignee: Wuxi Fortune Pharmaceutical Co Ltd. Priority date: 26/05/2016. Publication date: 14/06/2018. |